# TIL and Anti-PD1 in Metastatic Melanoma

> **NCT03638375** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Leiden University** · enrollment: 34 (estimated)

## Conditions studied

- Toxicity, Drug
- Adverse Drug Event
- Effects of Immunotherapy

## Interventions

- **DRUG:** Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha

## Key facts

- **NCT ID:** NCT03638375
- **Lead sponsor:** Leiden University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-31
- **Primary completion:** 2025-11-29
- **Final completion:** 2025-11-29
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2023-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03638375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03638375, "TIL and Anti-PD1 in Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03638375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*